Posted by Michael Wonder on 30 Nov 2023
New Zealand Pharmaceutical Schedule - 1 December 2023
1 December 2023 - The December 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.
There is one new listing of note this month; brentuximab vedotin (Adcetris) for patients with relapsed/refractory, CD30 positive Hodgkin lymphoma.
The PTAC recommended the listing of brentuximab vedotin in August 2016.
